List of Studies ( Metabolite:1-DeoxyCer 18:0;O/16:0)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
|---|---|---|---|---|---|---|---|
| ST000916 | AN001495 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma | Blood | Human | Fatty liver disease | LIPID MAPS | nM |
| ST000917 | AN001501 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine | Urine | Human | Fatty liver disease | LIPID MAPS | nM |
| ST001063 | AN001740 | Lipidomics analysis for aged mice organs | Adipose tissue | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001063 | AN001740 | Lipidomics analysis for aged mice organs | Brain | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001063 | AN001740 | Lipidomics analysis for aged mice organs | Liver | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001063 | AN001740 | Lipidomics analysis for aged mice organs | Muscle | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST000915 | AN001489 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | pmol/mg |
